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The increasing number of digital solutions developed for use in clinical health care
settings is accompanied by new challenges to develop and conduct clinical studies
that include eHealth technologies. Clinical study implementation plans often disregard
or underestimate the necessity of additional administrative and logistic tasks required at
clinical sites as well as ethical aspects to test digital solutions. Experiences made in the
run-up of an observational clinical feasibility study at three international clinical sites in the
framework of the MyPal project (https://mypal-project.eu/) result in recommendations to
avoid delays and barriers in the planning of such prospective studies in clinical and also
palliative care for increased efficiency.
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INTRODUCTION
The current era of rapid technological progress and its necessity in the medical field drives the
development of innovative eHealth technology. Application areas in medical care span from
personalized care (1), oncology (2–4) and palliative care (5, 6) to mental health (7–9). Many
national public health institutions have already acknowledged the urgency to adapt to a global
imminent digitalization trend (10, 11). The COVID-19 pandemic emphasized the importance
of digital health solutions (DHS) (12–14). To determine strengths and limitations of eHealth
interventions (3, 15), as well as to assess usability and evaluate the effectiveness of such technologies
in clinical research (16–18), recommendations and guidelines for conducting such studies are
becoming evenmore important. Moreover, eHealth and the use of artificial intelligence inmedicine
pose new technical and ethical challenges, which need to be discussed (19).
The conduct of clinical feasibility studies is an essential prerequisite to check the integrability of
DHS into daily clinical routine, to contribute to the evidence base as well as to evaluate effectiveness
and usability. This type of studies helps to become aware of problems that could occur during
development and implementation (18). Simultaneously, these studies entail new challenges that
often become already apparent in the preliminary phase of the respective studies at the clinical sites.
These include additional administrative and logistical burden to apply for ethical approval, to set
up the necessary technical infrastructure, the overall data management and study documentation,
as well as to familiarize and training of involved clinicians and health care professionals (HCPs)
working with the software or applications etc. Ethical aspects in particular must be profoundly
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considered given that data of vulnerable groups such as patients
with serious and severe diseases are digitally collected, processed
and possibly transferred. Therefore, they have to be managed in
compliance with both national and international regulations, e.g.,
the General Data Protection Regulation GDPR (EU 2016/679)
(20), which in particular considers health-related data as highly
sensitive and confidential data being assigned to the special
categories of personal data.
Due to the involvement of differently organized institutions
and bodies, multicenter studies demand an even higher degree of
coordination processes and mechanisms, information exchange
and general oversight over conduct and requirements for a
successful implementation of the planned study. Such challenges
can put a substantial strain on locally already established
implementation routines for clinical studies, impede and delay
the often tight schedule granted in project plans for setting up
clinical studies before patient recruitment can be initiated and
can lead to unforeseen additional costs (21).
In this policy brief, we portray experiences and observations
made in the course of setting up the currently running
observational prospective clinical feasibility MyPal-Child study
(MyPal4Kids) (22). Firstly, we provide an overview on the study
and its context. Secondly, we present deeper insights into the
necessary preparatory work that was required to be able to carry
out the study. These are structured around two main aspects:
ethical and legal considerations; and administrative tasks and
logistics at clinical sites. In each section, we present hands-on
recommendations for prospective projects and clinical studies in
order to overcome pitfalls and to avoid undesired fallbacks when
DHS are incorporated.
MYPAL4KIDS
A consortium of various clinical researchers and experts on
palliative care as well as software developers from seven
European countries joined efforts in the EU-funded project
MyPal (Grant Agreement No: 825872) to foster health care for
cancer patients by developing digital health platforms based on
electronic Patient-Reported Outcome (ePRO). With the help of
mobile apps, symptoms and current health states and hence
the needs of cancer patients and their caregiver(s) can be
communicated and reported to the relevant HCPs on site. The
evaluation of the digital health platforms will be the outcome
of two carefully designed clinical studies, which were running
during the draft of this present publication, with two groups of
cancer patients: adults and children in diverse health care settings
across Europe (23, 24).
The study involving pediatric cancer patients – MyPal4Kids –
focuses on the examination of the usage, usability and acceptance
of two mobile apps as part of a digital health platform, one
developed for children and adolescents from 6–17 years and one
for their legal guardians. These apps combine various functions
and advantages of ePRO-based protocols together with gaming
aspects in order to enhance motivation and participation among
patients. Symptom reporting is embedded in an entertaining
underwater-themed game. The gamification of such health
care apps is called “serious game” (25). Participating patients
can report their condition via an app to their treating HCPs
independently of in- or outpatient settings. Acting as a proxy for
their child, parents have the opportunity to report their child’s
health condition via the second app and to provide feedback
on quality of life, care satisfaction as well as the impact of the
disease on the family in the form of ePRO-based questionnaires.
The treating HCPs can check the symptoms reported by the
study participants in a web platform. The reported data and
information are visualized in tables and as graphs such that
developmental trajectories can be identified. Further, the HCPs
are able to add observed symptoms or specific treatment details
themselves on the platform. A local server is hosted for the study
at each clinical site. The necessary backend and database for the
apps and the web platform are installed on these servers. This
type of data deployment was chosen to assure data protection,
e.g. to restrict the access to person-related health data within the
premises of the clinical technical infrastructure and to enable data
transfer of anonymized data for final study evaluation.
The pediatric oncology departments of the University of
Saarland as the coordinating center and Hannover Medical
School in Germany as well as the University Hospital Brno in the
Czech Republic run MyPal4Kids (22).
SUSCEPTIBLE STEPS BEFORE THE
STUDY INITIATION
Ethical and Legal Study Evaluation
Pediatric cancer patients and their families constitute an
especially vulnerable group due to the seriousness of the disease
and its substantial overall impact on the whole family. The special
needs of this group and their relatives must be addressed by the
care staff at all times and appropriately looked after, starting with
the examination and at diagnosis during active disease treatment
and patient follow-up as well as accompanying or sole palliative
care. Protecting their dignity and privacy are of highest priority
and must always be guaranteed. Thus, regardless of whether the
study is pharmaceutical or, as in the case of MyPal4Kids, non-
pharmaceutical, the corresponding study protocol needs to be
profoundly revised with regard to the aforementioned points
and approved by the independent ethics committees (IECs) of
all clinical sites involved. Positive evaluations from independent
ethic committees verify the solidness of the submitted study
design and protocol. The essential premise is that changes and
remarks requested by the IECs are considered and the submitted
documents are revised accordingly. Besides the study protocol,
the submission to the IECs includes all information materials on
the study that will be made available to the study participants in
the context of a possible recruitment.
Planned clinical studies involving the testing of digital
innovations, such as applications or software, may encounter
additional requests from the IECs, asking for supplementary
information or specific documents. In the case of MyPal4Kids,
the ethical committees additionally solicited screenshots of each
screen view of every implemented mobile app questionnaire to
be provided in the respective national language version. The
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same applied for the information sheets and informed consent
forms which also had to contain comprehensive elucidations on
the technical measures planned to prevent unauthorized people
from gaining access to sensitive data as well as steps taken
to de-identify data. Clarifications for the study participants on
the purpose of the data collection, their data protection rights
and how to claim them, were applicable in compliance with
GDPR. One of the three IECs also demanded a statement by the
respective clinical site’s Data Protection Officer (DPO) regarding
the evaluation of the data protection and security measures
undertaken in the study, and the data management plan. The
official statement of DPO is a requirement which becomes more
and more relevant, reflecting the increasing number of DHS and
the legal landscape as shaped by GDPR, and has to be considered
in these kinds of studies in which personal data is collected online
via digital solutions.
Actionable Recommendations
If a clinical study is conducted in the framework of a bigger
research project, consider setting up a project-internal ethics
committee of corresponding expertise, ideally at the project’s
initiation. This will allow to closely supervise and support all
further planning steps of the clinical study with regard to the
ethical aspects of protecting the individuals’ rights and safety, the
frequency and sharing scheme of collected data, and overviewing
the respective content in the study protocol, information sheets
and informed consent forms. The same applies to the timely
consultation of competent DPO to supervise legal-compliance.
Make sure to timely collect all information regarding the
necessary submission procedures and requirements of the IECs
responsible for each clinical site involved. The applicable
international and national laws and regulations can vary widely
and depend on the type of clinical study design, especially
regarding clinical studies which involve medicinal products (26)
and medical devices (27). The design of the digital solution as
a medical device implicates stricter requirements and additional
costs, e.g., for the certification of software. Create a checklist of
documents and materials that need to be translated before the
submission. The scheduled meeting dates of the IECs should be
investigated in advance.
Depending on the age range of study participants, especially in
case of young study participants, it is necessary to draft different
versions of age-appropriate information sheets and informed
consent or assent forms.
Make sure to check if any other type of clearance is officially
required besides the clinical study’s ethical evaluation depending
on the type of study participants e.g., for pediatric patients.
Make sure in advance of the submission that the study
protocol and the development status of the digital innovation
have reached a stage where all study material, visualizations,
mock-ups, information on data management, etc., to be
submitted are at a final stage and no major changes are
expected subsequently. Investigate and openly communicate
in advance which changes and amendments would require
another evaluation by IECs. This important aspect can implicate
additional costs and delays if not taken care of appropriately.
In the case of multicenter studies, determine a steering clinical
site to make the first submission to the corresponding IEC. After
consideration and final approval of the requests for changes,
successively submit the revised versions to the remaining IECs
while referring to the ethical evaluation obtained. Be aware that
all subsequent requests for changes of successive IECs have
to be communicated in response to the previous committees.
If documents or text passages in the software require new
translations due to changes, this might result in additional
iterative back loops. The timeframe required for these loops
depends on the number and extent of remarked issues and
the study personnel available on site. This demands elaborate
planning and coordination. Regarding MyPal4Kids, it took 4
months from first submission to final ethical evaluation by the
IECs of all three clinical sites.
Administrative Tasks and Logistics
Further crucial milestones in the preliminaries of clinical
studies with DHS concern the planning and implementation
of the required technical infrastructure. This includes a
multiplicity of decisions on data deployment, data security,
data protection and handling of personal health data, data
transfer, permission roles and data visibility. These tasks require
efficient continuous communication and coordination between
the technical developers of the digital health solution to
be applied in the study as well as study representatives at
clinical sites, their respective information technology and legal
departments, and potentially DPOs. In particular, this includes
the risk and handling of differences in digital literacy, as well as
network connectivity problems.
A combination of access-controlled local and central data
deployment had been adopted in MyPal4Kids in order to
facilitate permission-based data protection and visibility. Local
web servers were set up at each clinical site to collect study data
independently from each other and one central server to store all
aggregated and anonymized study data for the final evaluation
and analysis.
Actionable Recommendations
Make sure to be aware at all times of the several inter-
dependencies when it comes to planning tasks and taking
decisions: the technical infrastructure set up usually intersects
with the content of the information sheets and informed consent
forms. This milestone in planning needs to be addressed and
finalized IN ADVANCE of the submissions to the IECs due to
the difficulty of retrospective modifications and amendments.
The planned technical infrastructure is the foundation to draft
and revise the required GDPR-compliant documents, such as:
Technical and Organizational Measures to ensure the security of
data processing (TOM), Records of Processing Activities and a
Data Protection Impact Assessment (DPIA) if required (20).
It is indispensable to schedule and perform a comprehensive
rehearsal testing of the digital solution in advance of the actual
study in order to test all processes planned for the study.
This allows to detect bugs and issues, which may impede or
disable usability, and helps to establish an iterative feedback loop.
Eventually, the engagement of HCPs is required to evaluate the
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usability of DHS. Therefore, it is advisable to involve HCPs in all
planning and development stages.
In case of multicenter studies and several project partners,
make sure to decide at an early time point how responsibilities
and tasks in data processing and evaluation will be allocated
among project members. Accordingly, contact the competent
legal departments and DPO to set up GDPR-compliant
Joint Controller Agreements or Data Processing Agreements,
depending on the settled responsibilities and rights. This can be
part of a general contractual agreement on the responsibilities of
the respective pair or group of project partners considering the
implementation of the clinical study. One crucial and often time-
consuming legal decision while drafting contractual agreements
in international multicenter studies is the choice of law and
the place of jurisdiction in case of breach of contract. For
example, some countries do not accept a place of jurisdiction in
another country.
The complexity of setting up technical infrastructure at
clinical sites necessitates regular and thorough communication
with all experts involved including IT departments, technical
developers and clinical study members. Consider following steps
when consulting the respective IT departments: servers have to
be in place and maintained, operating systems have to be set up
and corresponding installations of required software performed
including regular updates and backups. Single steps may require
confirmation by authorized personnel as well as clarifications
about technical specifications for mutual understanding of the
operating concept.
Consider individual differences in digital literacy among
the involved study personnel and participants at the clinical
site. Ensure sufficient training sessions for the personnel. This
includes drafting and handing out illustrative and supportive
training materials and instructions. A reference guide for HCP
can help keep track of the first steps in the study. These should
include credential creation steps, installation processes and steps
for the app, a feedback system and technical support for the
participants. In-app tutorials can be a useful tool to efficiently
provide required information.
Make sure that all clinical sites meet the technical
requirements to use the proposed digital health solution.
HCPs should be well equipped with sufficient electronic devices
to be able to use and/or demonstrate the respective application
or software. If the digital health solution requires an internet
connection, on-site access to Wi-Fi, as well as signal strength and
stability, should be verified in advance.
It is recommendable to schedule retrospective revisions
of scheduled project deliverables and documents which
address aspects such as data management plans, since
they are likely to be modified along the development
of the digital solution in advance of the preliminary
work for studies. If revisions are omitted, references
to these publicly official deliverables might hint on
already outdated information and lead to extended time
for clarifications.
DHS need to consider online and offline solutions for
applications due to the possibility of connection problems or
missing mobile data.
Be aware of and explore the necessity of sustainable funding
to develop, operate, and maintain the digital solution of
your project.
CONCLUSIONS
DHS have been investigated in clinical studies for a long time,
but not many have been widespread yet due to the challenges of
integrating them into everyday clinical practice while ensuring
usability and data security (28). Nevertheless, DHS offer
immense potential to address patient-centered care needs despite
challenges and obstacles for their long-term implementation in
clinical routine. We have exposed some challenges that may arise
at the early stages of implementation of DHS in clinical studies.
We provide a large range of useful actionable recommendations
on how to avoid common pitfalls and possible challenges that
might lead to delays. In particular, efficient communication and
exchange of information among all involved parties is a crucial
key for the successful set up and testing of DHS in clinical studies,
especially when different organizational entities are involved. It
is likely that following these recommendations will transition
into less problematic, smoother and efficient processes. This
in turn might make the provided DHS more attractive to the
already limited clinical resources at hand. The final evaluation
and analysis ofMyPal4Kids will topic further challenges observed
with regard to the time frame after study initiation and respective
recommendations as an outcome of the study.
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